Johnson & Johnson报告说,尽管达成了65M的反托拉斯解决办法,但是在肿瘤学和医学进步的推动下,Q4成果强劲,EPS收入为2.46美元,B收入为24.28B美元。 Johnson & Johnson reports strong Q4 results with $2.46 EPS and $24.28B revenue, driven by oncology and medtech progress, despite a $65M antitrust settlement.

Johnson & Johnson报告Q4收入为每股2.46美元,收入为242.8亿美元,净利润为28.46%,股本收益为33.04%。 Johnson & Johnson reported Q4 earnings of $2.46 per share on $24.28 billion in revenue, with a 28.46% net margin and 33.04% return on equity. 股票交易额为241.71美元,市场上限为582.19亿美元,52周范围在141.50美元至251.71美元之间。 The stock traded at $241.71, with a market cap of $582.19 billion and a 52-week range of $141.50 to $251.71. 分析师们保持"适度购买"的共识,平均目标价235.91美元,美国银行将目标提高到253美元,理由是瘤学和医疗技术方面取得了强的进展,包括FDA批准新的眼内透镜和膀癌药物的有希望的第一阶段结果. Analysts maintain a "Moderate Buy" consensus with a $235.91 average price target, as Bank of America raised its target to $253, citing strong pipeline progress in oncology and medtech, including FDA approval of a new intraocular lens and promising Phase 1 results for a bladder cancer drug. 尽管初步达成了6 500万美元的反托拉斯协议,内部销售了30 142股,但机构所有权仍然高达69.55%,公司红利收益为2.2%。 Despite a preliminary $65 million antitrust settlement and insider sales of 30,142 shares, institutional ownership remains high at 69.55%, and the company’s dividend yield stands at 2.2%.